Tocagen — Forte Biosciences — Proxy Contest (August 2023)
23 slides from Tocagen's proxy contest presentation, Aug 31, 2023
Slide 1: The Case for Boardroom Change at Forte Biosciences
The Case for Boardroom Change at Forte Biosciences Prepared by Camac Partners and ATG Capital August 2023
Slide 2: Legal Disclaimer
Legal Disclaimer The materials contained herein (the “Materials”) represent the opinions of Camac Fund, LP (together with its affiliates, “Camac”), ATG Capital Management, LLC (together with its affiliates, “ATG”) and the other participants named in the proxy solicitation (collectively, the “Group”
Slide 3: Table of Contents
01 Why We Are Here: The Case for Boardroom Change Table of 02 The Path Forward: Stockholder-Nominated Directors Contents 03 Appendix: Director Candidate Bios Concerned Stockholders of Forte Biosciences 3
Slide 4: Why We Are Here: The Case for Boardroom Change
Why We Are Here: The Case for Boardroom Change
Slide 5: Why We’re Here Today
Why We’re Here Today We believe Forte is in need of stockholder-designated directors following years of poor performance and worst-in- class governance under Chairman and CEO Dr. Paul Wagner and the current Board: Extremely Dilutive Capital Blatant Disregard for Adopting “Poison Pill” with Raises St
Slide 6: About Camac and ATG
About Camac and ATG Our Group owns an ~8.5% stake in Forte, making us one of the Company’s largest stockholders • Camac has a track record of using private and public • ATG has used private and public engagement with its engagement with North American companies to portfolio companies to improve gove
Slide 7: About Forte Biosciences
About Forte Biosciences We believe that Forte is a biotechnology company that had a singular asset, FB-401 • Forte’s singular asset for atopic dermatitis failed in its phase 2 clinical FBRX Stock Price Since Initial Public trial in September 2021 Offering (“IPO”) (1) $60 • The Company made what appe
Slide 8: Significant Value Destruction Under Chair and CEO Dr. Wagner
Significant Value Destruction Under Chair and CEO Dr. Wagner Forte has delivered negative total stockholder returns (“TSR”) and significantly underperformed relevant indices over all relevant time horizons 1-Year TSR 3-Year TSR TSR Since IPO 20% 14.7% 1.5% 3.8% 0.7% 0% -0.2% -3.8% -20% -13.9% -40% -
Slide 9: Investors Growing Frustrated with Management and the Board
Investors Growing Frustrated with Management and the Board Tellingly, between May 24, 2022 and August 9, 2022, four new Schedule 13Ds were filed by the Company’s stockholders, each of which disclosed dissatisfaction with leadership and began pushing for change: “ It has become clear to me that share
Slide 10: Dr. Wagner Does Not Appear Aligned with Forte Stockholders
Dr. Wagner Does Not Appear Aligned with Forte Stockholders We question how much Dr. Wagner believes in the long-term viability of Forte, given he has been an active seller in recent years • Dr. Wagner was worth more than $100 million on paper when Forte traded over $40 per share in 2020 • After FB-4
Slide 11: Timeline of Forte’s Anti-Stockholder Actions
Timeline of Forte’s Anti-Stockholder Actions May 2022 Fall 2022 – Today • BML files ~6% position (initially as a 13G • The Company appoints two non-stockholder-related directors filer) with significant ties to the CEO • The Company announces they are all in on • The Company delays the 2023 Annual Me
Slide 12: Forte’s Highly Speculative “Strategic” Pivot
Forte’s Highly Speculative “Strategic” Pivot Look at what they do, not what they say… • Despite Forte peddling FB-102 as demonstrating potentially “best in class activity,” the reality is that the compound is still in preclinical indication • We are now in the second half of 2023 and Forte is guidin
Slide 13: Worst-In-Class Governance: Dilutive and Defensive July 2023 Private Placement
Worst-In-Class Governance: Dilutive and Defensive July 2023 Private Placement Forte’s 2023 Private Placement appears to us to have been substantially motivated by an attempt to thwart a stockholder vote • Forte executed the highly dilutive 2023 Private Placement, which involved placing over 15 milli
Slide 14: Worst-In-Class Governance: Raising Money Below Cash
Worst-In-Class Governance: Raising Money Below Cash We believe Forte’s decision to sell the majority of its shares at prices well below its liquidation value was a clear entrenchment maneuver by the current Board • In our view, a stock that trades below cash per share is a stock that investors belie
Slide 15: The Path Forward: Stockholder-Nominated Directors
The Path Forward: Stockholder-Nominated Directors
Slide 16: We Believe Change is Warranted and Our Nominees Will Bring a Stockholder Perspective
We Believe Change is Warranted and Our Nominees Will Bring a Stockholder Perspective and the Skills Needed to Deliver Results • We believe adding two highly qualified, independent directors with capital allocation and investment management experience to the Company’s Board is not only reasonable, bu
Slide 17: Our Legal Efforts
Our Legal Efforts • Camac filed a complaint (2023-0817-MTZ) asking the Delaware Chancery Court (the “Court”) to issue an order blocking the defendants from counting votes cast at the Annual Meeting that were acquired via the PIPE • Camac’s Delaware legal action seeks to hold the Company, Dr. Wagner
Slide 18: Independent Director Candidate: Michael Hacke
Independent Director Candidate: Michael Hacke We believe Mr. Hacke’s investment advisory, capital markets and capital allocation expertise will be additive to Forte’s Board • Founder of Steel City Capital Investments, LLC, the general partner of a long-biased investment partnership with a value-orie
Slide 19: Independent Director Candidate: Chris McIntyre
Independent Director Candidate: Chris McIntyre We believe Mr. McIntyre’s 15+ years of investment experience, including in public equities, private equity, distressed debt and restructurings, will be additive to Forte’s Board • Founder, Chief Investment Officer and Managing Partner of McIntyre Capita
Slide 20: Our Vision for Forte
Our Vision for Forte Our director candidates are committed to acting in stockholders’ best interests and will work diligently to improve Forte’s corporate governance and focus on the right initiatives, including: ✓ Promptly investigating all options to maximize stockholder value ✓ Maximizing the Boa
Slide 21: Appendix: Director Candidate Bios
Appendix: Director Candidate Bios
Slide 22: Michael Hacke Biography
Michael Hacke Biography Michael G. Hacke is the Managing Member of Steel City Capital Investments, LLC, the general partner of Steel City Capital, LP, a long-biased investment partnership which employs a value-oriented investing strategy, which he founded in May 2018. Prior to founding Steel City Ca
Slide 23: Chris McIntyre Biography
Chris McIntyre Biography Chris McIntyre founded McIntyre Capital Management, LP, an investment firm, in January 2017 and has served as Chief Investment Officer and Managing Partner since its founding. McIntyre Capital, on behalf of its funds and accounts, makes concentrated investments in value-orie